Literature DB >> 32001828

The association of antihypertensive use and depressive symptoms in a large older population with hypertension living in Australia and the United States: a cross-sectional study.

Bruno Agustini1, Mohammadreza Mohebbi2,3, Robyn L Woods4, John J McNeil4, Mark R Nelson5, Raj C Shah6, Anne M Murray7, Michael E Ernst8,9, Christopher M Reid4,10, Andrew Tonkin4, Jessica E Lockery4, Michael Berk2,11.   

Abstract

Cardiovascular drugs impact many pathways involved in depression pathophysiology and treatment. However, their distinct impact on mood is underrecognized and the literature is conflicting. Therefore, using a very large and well-characterised sample of older adults with hypertension, we aimed to investigate the prevalence of depressive symptoms in users of different antihypertensive classes. We analysed baseline data from 14,195 older individuals with hypertension enroled in a large clinical trial. Median age was 75 years. The association of antihypertensive use by class and depression prevalence, as measured by a validated depression scale, was determined using logistic regression models. Multivariable logistic models were implemented to account for important confounding factors. Our analyses showed a positive association between depressive symptoms and the use of beta blockers (BB) (OR: 1.37; 95% CI: 1.17-1.60, p < 0.01), compared with users of other antihypertensive classes. All other classes of antihypertensives (including angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, and calcium channel blockers) were not significantly associated with depressive symptoms. In secondary analysis, this relationship was stronger for lipophilic (39%) and nonselective BB (52%) compared with hydrophilic (26%) and selective medications (31%), respectively. This study adds further evidence for a probable association between BB and depression in a large sample of older adults with hypertension and no history of cardiovascular disease or heart failure. These findings should regenerate interest and increase awareness of clinicians about the possible adverse effects of these medications in an otherwise healthy older population.

Entities:  

Year:  2020        PMID: 32001828      PMCID: PMC7390661          DOI: 10.1038/s41371-020-0303-y

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  10 in total

1.  Beta-blockers and depression in elderly hypertension patients in primary care.

Authors:  Lianne Ringoir; Susanne S Pedersen; Jos W M G Widdershoven; Francois Pouwer; Josephine M L Keyzer; Arnold C Romeijnders; Victor J M Pop
Journal:  Fam Med       Date:  2014-06       Impact factor: 1.756

2.  Beta blocker therapy is associated with reduced depressive symptoms 12 months post percutaneous coronary intervention.

Authors:  Linda C Battes; Susanne S Pedersen; Rohit M Oemrawsingh; Robert J van Geuns; Ibtihal Al Amri; Evelyn Regar; Peter P T de Jaegere; Patrick Serruys; Ron T van Domburg
Journal:  J Affect Disord       Date:  2011-10-26       Impact factor: 4.839

Review 3.  Neurobiological correlates of emotional processing in Parkinson's disease: A systematic review of experimental studies.

Authors:  Anja J H Moonen; Anke Wijers; Kathy Dujardin; Albert F G Leentjens
Journal:  J Psychosom Res       Date:  2017-07-18       Impact factor: 3.006

Review 4.  Management of hypertension in the elderly.

Authors:  Eduardo Pimenta; Suzanne Oparil
Journal:  Nat Rev Cardiol       Date:  2012-03-13       Impact factor: 32.419

Review 5.  A review on the putative association between beta-blockers and depression.

Authors:  Daniëlle E P Verbeek; Jerry van Riezen; Rudolf A de Boer; Joost P van Melle; Peter de Jonge
Journal:  Heart Fail Clin       Date:  2011-01       Impact factor: 3.179

6.  Clinically relevant depression in old age: An international study with populations from Canada, Latin America and Eastern Europe.

Authors:  Alban Ylli; Malgorzata Miszkurka; Susan P Phillips; Jack Guralnik; Nandini Deshpande; Maria Victoria Zunzunegui
Journal:  Psychiatry Res       Date:  2016-04-29       Impact factor: 3.222

7.  Initiation of β-blocker therapy and depression after acute myocardial infarction.

Authors:  Anil M Ranchord; John A Spertus; Donna M Buchanan; Kensey L Gosch; Paul S Chan
Journal:  Am Heart J       Date:  2015-12-17       Impact factor: 4.749

Review 8.  Energetic stress: The reciprocal relationship between energy availability and the stress response.

Authors:  C S Harrell; C F Gillespie; G N Neigh
Journal:  Physiol Behav       Date:  2015-10-09

9.  Prevalence of Prescription Medications With Depression as a Potential Adverse Effect Among Adults in the United States.

Authors:  Dima Mazen Qato; Katharine Ozenberger; Mark Olfson
Journal:  JAMA       Date:  2018-06-12       Impact factor: 56.272

Review 10.  The genetic overlap between mood disorders and cardiometabolic diseases: a systematic review of genome wide and candidate gene studies.

Authors:  A T Amare; K O Schubert; M Klingler-Hoffmann; S Cohen-Woods; B T Baune
Journal:  Transl Psychiatry       Date:  2017-01-24       Impact factor: 6.222

  10 in total
  10 in total

1.  Patterns of Association between Depressive Symptoms and Chronic Medical Morbidities in Older Adults.

Authors:  Bruno Agustini; Mojtaba Lotfaliany; Robyn L Woods; John J McNeil; Mark R Nelson; Raj C Shah; Anne M Murray; Michael E Ernst; Christopher M Reid; Andrew Tonkin; Jessica E Lockery; Lana J Williams; Michael Berk; Mohammadreza Mohebbi
Journal:  J Am Geriatr Soc       Date:  2020-05-13       Impact factor: 5.562

2.  Brain-penetrant calcium channel blockers are associated with a reduced incidence of neuropsychiatric disorders.

Authors:  Lucy Colbourne; Paul J Harrison
Journal:  Mol Psychiatry       Date:  2022-05-26       Impact factor: 15.992

Review 3.  Drug Safety in Episodic Migraine Management in Adults. Part 2: Preventive Treatments.

Authors:  Abigail L Chua; Sandhya Mehla; Yulia Y Orlova
Journal:  Curr Pain Headache Rep       Date:  2022-05-19

4.  Onset and recurrence of psychiatric disorders associated with anti-hypertensive drug classes.

Authors:  Lucy Colbourne; Sierra Luciano; Paul J Harrison
Journal:  Transl Psychiatry       Date:  2021-05-26       Impact factor: 6.222

5.  Influence of Hostility on 24-Hour Diastolic Blood Pressure Load in Hypertension Patients with Depressive Disorders.

Authors:  Feihuan Cui; Na Zhang; Jin Yi; Yulan Liang; Qi Liu
Journal:  Med Sci Monit       Date:  2021-02-28

Review 6.  Is there a link between depression, neurochemical asymmetry and cardiovascular function?

Authors:  A B Segarra; I Prieto; M Martínez-Cañamero; Manuel Ramírez-Sánchez
Journal:  AIMS Neurosci       Date:  2020-09-28

Review 7.  Neuropsychiatric Consequences of Lipophilic Beta-Blockers.

Authors:  Sabina Alexandra Cojocariu; Alexandra Maștaleru; Radu Andy Sascău; Cristian Stătescu; Florin Mitu; Maria Magdalena Leon-Constantin
Journal:  Medicina (Kaunas)       Date:  2021-02-09       Impact factor: 2.430

8.  Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers and risk of depression among older people with hypertension.

Authors:  Thomas T van Sloten; Patrick C Souverein; Coen DA Stehouwer; Johanna Hm Driessen
Journal:  J Psychopharmacol       Date:  2022-04-07       Impact factor: 4.562

9.  Associations of Cardiovascular Agents and Metformin with Depression Symptoms: A Cross-Sectional Analysis from the HUNT Study, Norway.

Authors:  Ivana Bojanić; Ottar Bjerkeset; Lana J Williams; Michael Berk; Erik R Sund; Hege Sletvold
Journal:  Drugs Real World Outcomes       Date:  2022-07-18

10.  Association Between Lipophilic Beta-Blockers and Depression in Diabetic Patients on Chronic Dialysis.

Authors:  Robin Lengton; Robbert W Schouten; Els Nadort; Elisabeth Fc van Rossum; Friedo W Dekker; Carl Eh Siegert; Ellen K Hoogeveen
Journal:  Clin Med Insights Endocrinol Diabetes       Date:  2022-08-29
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.